Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were $12.2 Billion, increasing 9% (+11% Adjusting for Foreign Exchange) Growth Portfolio Revenues were $5.6 Billion, increasing 18% (+21% Adjusting for Foreign Exchange) GAAP EPS was $0.83 and Non-GAAP EPS was $2.07; Includes Net Impact of $(0.04) Per Share for GAAP EPS and Non-GAAP EPS Due to...Read more
Diluted EPS of $2.16; Adjusted Diluted EPS of $2.42 Reaffirms 2024 Adjusted Diluted EPS Guidance Floor of Greater Than $6.80 Adjusted diluted EPS of $2.42, up 15% from $2.10 in the second quarter of 2023. Premium and service revenues of $36.0 billion in the second quarter of 2024. Membership increase of 34% in Marketplace, compared to the second quarter of 2023. ST. LOUIS, July 26, 2024 /PRNewswire/ -- Centene...Read more
Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook ACTON, Mass. / Jul 26, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary revenue results for the three months ended June 30, 2024. The Company plans to report full second...Read more
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024. For the six-months ended June 30, 2024, Legend Biotech expects to record an adjusted net loss for the period of approximately $94.7 million to $109.7 million. See “Use of Non-IFRS Financial Measures”...Read more
Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $14.462 Billion, an Increase of 4.3 Percent on a Reported Basis and 5.6 Percent on an Operational Basis Second-Quarter...Read more
Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1 CAMBRIDGE, United Kingdom / Jul 25, 2024 / Business Wire / AstraZeneca: Revenue and EPS summary H1 2024 % Change Q2 2024 % Change $m Actual CER $m Actual CER - Product...Read more
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational studies across efgartigimod and empasiprubart by end of 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) Regulated Information – Inside Information July 25, 2024 7:00 AM CET - Amsterdam, the Netherlands – argenx SE...Read more
SAN DIEGO / Jul 25, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic1 basis. U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic1 basis, all on a...Read more
Conference Call Scheduled for 9 a.m. EDT Today EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%. Reported-diluted EPS of $1.51,...Read more
SAN JUAN CAPISTRANO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the second quarter of 2024, reporting GAAP diluted earnings per share of $1.22 and adjusted...Read more
Continued strong performance with 2Q24 financial results Raising full year 2024 profit outlook PLANO, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended June 28, 2024. Second Quarter 2024 Highlights (compared to Second Quarter 2023, except as noted) Sales increased 9% to $436 million, with organic growth of 5%. GAAP net income...Read more
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 ROOT, Switzerland / Jul 25, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend...Read more
Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024. Key Second Quarter Highlights and...Read more
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts...Read more
Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* (pembrolizumab) to unleash potential efficacy, while maintaining safety comparable to pembrolizumab alone Poster planned at European Society of Medical Oncology (ESMO) Congress 2024 in September for ADG126 in combination...Read more
WALTHAM, Mass. / Jul 24, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04. Second quarter adjusted EPS increased 4% to $5.37. Advanced our proven...Read more
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per...Read more
IRVINE, Calif. / Jul 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be...Read more
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 2024 and 9.9% on quarter two 2023. Quarter two revenue of $2,120.2 million representing an increase of 4.9% on prior year revenue and 5.3% on a constant...Read more
Reaffirms Full Year 2024 Earnings Guidance LONG BEACH, Calif. / Jul 24, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported second quarter 2024 GAAP earnings per diluted share of $5.17 and adjusted earnings per diluted share of $5.86. Financial results are summarized below: Three months ended Six months ended June 30, June...Read more
Net income available to common shareholders in second quarter 2024 was $259 million, or $2.64 per diluted share Adjusted diluted earnings per share1 was $2.31 in second quarter 2024 Consolidated Adjusted EBITDA1 in second quarter 2024 of $945 million increased 12.1% over second quarter 2023 Second quarter 2024 Ambulatory Care Adjusted EBITDA of $447 million increased 20.8% over second quarter 2023 Board of Directors has authorized a...Read more
Consolidated Results of Operations, As Reported and As Adjusted – Three-month periods ended June 30, 2024 and 2023: KING OF PRUSSIA, Pa., July 24, 2024 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $289.2 million, or $4.26 per diluted share, during the second quarter of 2024, as compared to $171.3 million, or $2.42 per diluted share, during the...Read more
CINCINNATI / Jul 24, 2024 / Business Wire / Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2024, versus the comparable prior-year period. Changes to Non-GAAP...Read more
Conference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 In Vivo Data From Novel Amylin Agonist Program Reported at...Read more
Second Quarter Revenues of $399.1 Million Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year GAAP Net Income from Continuing Operations of $94.7 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.55 Company Reiterates 2024 Financial Expectations DUBLIN, July 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the...Read more
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023. Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related...Read more
Raises Second Half 2024 Revenue Estimates, Reaffirms Full-Year 2024 Cash Flow Forecast Revenue of $426.3 million, in line with expectations. Net income and diluted EPS of ($1.8) million and ($0.02); includes $0.22 impact of client restructuring charges. Reported and adjusted cash flow from operations of $16.3 million and ($2.4) million. Raises Q3 and Q4 revenue estimates to $425.0 to $435.0 million and $430.0 to $440.0...Read more
FRANKLIN, Tenn. / Jul 24, 2024 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) (the “Company”) today announced financial and operating results for the three and six months ended June 30, 2024. The following highlights the financial and operating results for the three months ended June 30, 2024. Net operating revenues totaled $3.140 billion. Net loss attributable to Community Health Systems, Inc. stockholders was $(13)...Read more
Software Operations Bookings Up 10.3% From Prior Quarter Year-Over-Year Software Revenue Performance Driven by Growth in Maintenance and Services ALEXANDRIA, Va. / Jul 24, 2024 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced results for the second quarter ended June 30, 2024. In addition, the Company’s Board of Directors declared a regular quarterly dividend of...Read more
WASHINGTON, July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results Net earnings were $907 million, or $1.22 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.72. Revenues decreased 3.0%...Read more
Raises 2024 Guidance NASHVILLE, Tenn. / Jul 23, 2024 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2024. Key second quarter metrics (all percentage changes compare 2Q 2024 to 2Q 2023 unless otherwise noted): Revenues totaled $17.492 billion Net income attributable to HCA Healthcare, Inc. totaled $1.461 billion, or $5.53 per diluted...Read more
Second quarter revenues of $2.40 billion, up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2% from 2023 Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billion; reported diluted EPS now expected to be between $7.57 and $7.77; and adjusted diluted EPS expected to be between $8.80 and $9.00 SECAUCUS, N.J.,...Read more
Plans to Release Full Results on Friday, August 2 Before the NYSE Open RICHMOND, Va. / Jul 23, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) today announced selected preliminary financial results for the quarter ended June 30, 2024 as noted in the table below. The Company also reaffirmed its outlook for the full year 2024 as noted below in advance of its second quarter 2024 earnings announcement and conference...Read more
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated...Read more
Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease of 4.1% from net new business awards of $574.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of...Read more
NASHVILLE, Tenn. / Jul 22, 2024 / Business Wire / HealthStream, Inc. (the “Company”) (Nasdaq: HSTM), a leading healthcare technology platform for workforce solutions, announced today results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenues of $71.6 million in the second quarter of 2024, up 3.4% from $69.2 million in the second quarter of 2023 Operating income of $4.4 million in the second quarter of 2024, up...Read more
BELLEVUE, Wash. / Jul 19, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo’s CEO and...Read more
Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30,...Read more
SUNNYVALE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2024. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023. The Company placed 341 da Vinci surgical systems, compared...Read more
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024. Fourth Quarter Financial Highlights: Fourth quarter revenue increased 7% to $14 million Adjusted EBITDA fourth quarter income of...Read more
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* Significant new product pipeline progress including TREMFYA IBD and subcutaneous...Read more
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders INDIANAPOLIS / Jul 17, 2024 / Business Wire / Elevance Health, Inc. (NYSE: ELV) reported second quarter 2024 results. “Second quarter results reflect the power of our diversified business and thoughtful...Read more
Revenues of $98.9 Billion Grew Nearly $6 Billion Year Over Year, Led by Optum Consumers Served by UnitedHealthcare’s Commercial Domestic Offerings Grew 2.3 Million Year to Date Cash Flows from Operations were $6.7 Billion or 1.5x Net Income Second Quarter Earnings of $4.54 Per Share Reflect Classification of Remaining South American Operations as Held for Sale and Cyberattack Impacts Adjusted Earnings of $6.80 Per Share Include $0.28...Read more
LATHAM, N.Y. / Jul 16, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024. Fiscal Year 2024 Fourth Quarter...Read more
OLDSMAR, Fla. / Jul 15, 2024 / Business Wire / Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2024. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2024 were $8.0 million compared to $7.8 million for the second quarter of fiscal 2023, a...Read more
BOULDER, CO / ACCESSWIRE / July 15, 2024 / Encision Inc. (OTCPK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 fourth quarter that ended March 31, 2024. The Company posted quarterly net revenue of $1.53 million for a quarterly net loss of $409 thousand, or $(0.03)...Read more
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer Strengthened financial position ending the quarter with cash and marketable securities of $452.5 million SAN...Read more
Submitted NDA for sebetralstat as first-ever, oral on-demand treatment for HAE attacks, a pivotal moment for the HAE community Potential FDA approval and launch of sebetralstat in first half 2025 CAMBRIDGE, Mass. & SALISBURY, England / Jul 11, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today provided an operational update and released financial results for the fiscal year ended April 30,...Read more
Q3 Fiscal 2024 Highlights Revenue of $4.3 million, a 1.9% decline over Q2 2024 Gross profit of $1.0 million, a 9.8% decline over Q2 2024 Cash position of $3.7 million as of May 31, 2024 Transitioned out of Canadian clinical operations through an agreement with the Canadian Centre for Psychedelic Healing ("Field Trip Health") Enrolment in Numinus training programs increased to over 1,650 learners, compared to over 1,400 in Q2 2024,...Read more
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million MONTREAL, July 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company...Read more
IRVINE, Calif / Jul 09, 2024 / Business Wire / Masimo Corporation (Nasdaq: MASI) today announced preliminary revenue and select financial results for the second quarter ended June 29, 2024. Preliminary Second Quarter 2024 Revenue and Select Financial Results: Consolidated revenue is expected to be approximately $496 million, representing 9% growth on a reported basis and 10% growth on a constant currency basis; Healthcare revenue is...Read more
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance LANCASTER, Calif. / Jul 02, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported...Read more
Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History Signed $30 Million in Net New Business Resulting in Backlog of $193 Million New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Three-Year Expansion Program Completed FY 2025 Revenue Guidance of Between $160 Million and $168 Million TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid...Read more
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, "Over the past several years, our product roadmap has expanded from our Nutraceutical business to complementary markets such as Pharmaceutical, Dental,...Read more
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows: Strong preliminary revenue growth with total revenues for the second quarter between $196 -...Read more
Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Consolidated revenues for Fiscal 2024 were $56.6 million, an increase of $22.4 million or...Read more
Received reimbursement from insurance payors for the first time in Company history during first quarter, which is expected to increase as a percentage of total revenue going forward Following its IPO in early June, the Company has sufficient capital to fund operations and execute on its growth strategy for at least the next 12 months SALT LAKE CITY, UT / ACCESSWIRE / June 28, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company")...Read more
Lowering Guidance in Continued Challenging Environment; Provides Strategic Update Third quarter financial highlights Third quarter earnings per share (EPS)* was $0.40 compared to earnings per share of $0.14 in the year-ago quarter which included a non-cash impairment of pharmacy license intangible assets in Boots UK Adjusted EPS** was $0.63, down 36.6 percent on a constant currency basis compared to the year-ago quarter,...Read more
SEATTLE, June 27, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2024. “Accolade's physician-led advocacy approach to solving the Physician Gap is increasing accessibility to healthcare and improving outcomes for the millions of lives we service. We will continue to push our leadership in Healthcare AI and a proven engagement model that is driving...Read more
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development Results presented at the Annual Meeting of the AACR showed single agent MDNA11 response rate of 29% (4/14) in patients with checkpoint resistant...Read more
FY24 revenue up 25.2% YOY FY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continue FY24 operating expenses lower by 17.6% YOY Negative EBITDA reduced by $7.2 million - an improvement of 44.6% -- accelerating the Company's path to breakeven and EBITDA positive REDWOOD CITY, CA / ACCESSWIRE / June 27, 2024 / Biotricity Inc....Read more
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the...Read more
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE